Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gilbert van den Tillaart"'
Autor:
Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas, Hans van Eenennaam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents a
Externí odkaz:
https://doaj.org/article/7bdacc0cad7a402abca3856640245c5f
Autor:
Gilbert van den Tillaart, Sander M.J. van Duijnhoven, David Lutje Hulsik, Erik Voets, Andrea van Elsas, Peter van Zandvoort, Paul Vink, Inge Reinieren-Beeren, Maurice Habraken, Joost Kreijtz, Lilian Driessen, Hans van Eenennaam, Wout Janssen, Marc Parade, Sanne Spijkers, Joost Rens
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Background Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents are curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd5c681a7efe313711ff0ec36bf0dcd
https://doi.org/10.1186/s40425-019-0772-0
https://doi.org/10.1186/s40425-019-0772-0